These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33707305)

  • 1. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.
    Lee MMY; Ghouri N; McGuire DK; Rutter MK; Sattar N
    Diabetes Care; 2021 May; 44(5):1236-1241. PubMed ID: 33707305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2020; 14(4):715-722. PubMed ID: 32470852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.
    Tang H; Kimmel SE; Smith SM; Cusi K; Shi W; Gurka M; Winterstein AG; Guo J
    Diabetes Care; 2022 Apr; 45(4):1007-1012. PubMed ID: 35349656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Cotter G; Davison BA; Edwards C; Senger S; Teerlink JR; Zannad F; Nielsen OW; Metra M; Mebazaa A; Chioncel O; Greenberg BH; Maggioni AP; Ertl G; Sato N; Cohen-Solal A
    Am Heart J; 2021 Oct; 240():73-80. PubMed ID: 34107289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    EClinicalMedicine; 2022 Dec; 54():101697. PubMed ID: 36263397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.
    Qiu M; Ding LL; Zhang M; Lin JH; Wei XB; Huang H
    Diabetes Ther; 2020 Oct; 11(10):2429-2440. PubMed ID: 32852698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2022 Aug; 45(8):1900-1906. PubMed ID: 35775451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
    JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.
    Diallo A; Carlos-Bolumbu M; Renard PE; Galtier F
    Diabetes Obes Metab; 2023 Jan; 25(1):166-176. PubMed ID: 36057779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H; Liu T; Wang L; Ji Q
    Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.